低剂量利妥昔单抗对成人特发性血小板减少性紫癜患者有效。
Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura.
作者信息
Zaja Francesco, Battista Marta Lisa, Pirrotta Maria Teresa, Palmieri Salvatore, Montagna Michela, Vianelli Nicola, Marin Luciana, Cavallin Margherita, Bocchia Monica, Defina Marzia, Ippoliti Micaela, Ferrara Felicetto, Patriarca Francesca, Avanzini Maria Antonietta, Regazzi Mario, Baccarani Michele, Isola Miriam, Soldano Franca, Fanin Renato
机构信息
Clinica Ematologica, Azienda Ospedaliera Universitaria, piazza S. Maria della Misericordia, 33100 Udine, Italy.
出版信息
Haematologica. 2008 Jun;93(6):930-3. doi: 10.3324/haematol.12206. Epub 2008 Apr 9.
Rituximab 375 mg/m(2) weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50 x 10(9)/L) and complete responses (platelet count > 100 x 10(9)/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose.
利妥昔单抗375mg/m²，每周一次，共四周，对免疫性血小板减少症患者有显著疗效。我们评估了低剂量利妥昔单抗（静脉注射100mg，每周一次，共4周）对28例成人特发性血小板减少性紫癜患者的疗效。总体缓解（血小板计数>50×10⁹/L）和完全缓解（血小板计数>100×10⁹/L）分别在21/28（75%）和12/28（43%）的患者中实现。达到缓解的中位时间和完全缓解的中位时间分别为31天和44天。中位随访11个月（范围3 - 18个月）后，7/21（33%）的患者复发，3例患者需要进一步治疗。在特发性血小板减少性紫癜患者中，低剂量利妥昔单抗似乎显示出与标准剂量相似的疗效。
Zotero 插件